Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
read more >
Zacks Equity Research (8/9/17)
"Inovio Pharmaceuticals Inc.'s VGX-3100, an HPV immunotherapy, is the most advanced candidate in the company's pipeline that is currently being developed for the treatment of HPV-16/18-related high-grade cervical dysplasia. Inovio initiated a phase III study to evaluate VGX-3100 for treatment of cervical dysplasia caused by human papillomavirus. . .during the same period, the company started a phase II study to examine the efficacy of VGX-3100 in women with HPV-related vulvar neoplasia."

Ram Selvaraju, H.C. Wainwright & Co. (8/9/17)
"Inovio Pharmaceuticals Inc. ended the quarter with $92M in cash and subsequently closed an underwritten public offering of 12.5M common shares at $6.00 per share. . .we estimate that the company's pro forma cash position after the offering should be sufficient to fund at least 18 months of operations. Inovio reported top-line revenues of $20.4M in 2Q17, handily beating our original projection. . .this was primarily driven by the recognition of $13.8M in revenue from MedImmune. . .we reiterate our Buy rating and 12-month price target of $13 per share on INO."

Jason McCarthy, Maxim Group (8/9/17)
"Inovio Pharmaceuticals Inc. reported 2Q17 with revenue of $20.6M (collaborations, partnerships) and operating expenses of $30M for a net loss of $9.5M. The company ended the period with $92M in cash and raised $75M in July. . .the clinical hold on VGX-3100 pivotal study was lifted in June and the trial is underway. Twenty seven sites have been opened already and 50 should be opened by year end. . .Inovio is a pivotal company and multiple pipeline programs continue to advance. With multiple studies underway, more initiating and data points ahead in 2017, we see multiple catalysts to drive valuation higher."

Charles Duncan, Piper Jaffray & Co. (8/9/17)
"Inovio Pharmaceuticals Inc. reported 2Q17 financial results, including $92M in cash prior to the recent $71M capital raise. Our model projects proforma cash to fund the company at least into 2H19. . .we expect the key value-creating events for the stock to be enrollment and potentially even results from the lead REVEAL program in cervical dysplasia, as well as proof-of-concept results in other cancers/pre-cancers which inform visibility on direction of the broader pipeline. . .we see the bolstered balance sheet as supporting execution of its lead program, and well as set of hypothesisgenerating Phase IIs."

Charles Duncan, Piper Jaffray & Co. (8/4/17)
"Inovio Pharmaceuticals Inc. recently raised $70.5M in net cash from a secondary offering, bringing proforma 3Q17 cash in our model to $163M. We believe this cash funds the company at least into 2H19, and potentially through results from REVEAL, the recently initiated Phase III in cervical dysplasia, or at least significant progress towards results. . .we have recently performed additional diligence on REVEAL and believe the program is well-designed to demonstrate clinically meaningful results which highlight potential advantages over surgery. . .we are maintaining our $14 PT based on the fundamental progress we anticipate in the next 12-18 months for this platform."

Ram Selvaraju, H.C. Wainwright & Co. (7/27/17)
"Inovio Pharmaceuticals Inc. closed an underwritten public offering of 12.5M common shares at $6.00 per share. . .we estimate that the company’s pro forma cash position after the offering could be around $160M and should be sufficient for 18 months of operations. . .we reiterate our Buy rating and 12-month price target of $13. Inovio is slated to report 2Q17 financial results on August 8, 2017."

A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018.
read more >
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors.
read more >
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts.
read more >
J. Joseph Kim
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses.
read more >

More Expert Comments

Experts Following This Company

Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.